Read all about it! The latest news from the medical technology experts

IOPvet gets the 'thumbs up' around the world

Ingeneus launches IOPvet device

Further patents issued in key regions for the eyePressure device

Revolutionising high eyePressure detection around Australia - and even in the Antarctic

Patents issued in key regions for the eyeTelehealth Platform

Patent issued for Ingeneus' eyeConnect device in China

Patents issued in the US and China for eyeTelehealth products

World first eyeConnect unveiled at Frankston Hospital

Ingeneus products - Good Design Awards winners

Ingeneus products in Good Design Awards finals

Ingeneus appoints new GM Manufacturing

Ingeneus launches eyePressure device

Ingeneus works with SMART Arm

Ingeneus on the move

Ingeneus develops new remote assessment tool

Medical device treats Ocular Pathologies during Vitreoretinal Surgery

V-Patch Medical Systems: reaching the hearts of the travelling public

Double Success for Ingeneus in Government Program

Ingeneus advocates change to the Therapeutic Goods Administration (TGA)

Ingeneus Exhibits at AusMedtech 2011 Conference

Dynamic enhancement of Ingeneus QMS for medical devices and biomedical applications

Exciting opportunities at BiOS 2011 for Ingeneus

Ingeneus engages with emerging markets

New branding & website under Design Vic Business Immersion program

Ingeneus completes software training with its clients

Ingeneus passes TGA Surveillance Audit

Ingeneus signs licensing agreement for low cost diabetic retinopathy system

Ingeneus launches eyePressure device


Ingeneus advocates change to the Therapeutic Goods Administration (TGA)

For Australian medical device manufacturers intending to supply in Australia, their only route to market relies solely on the TGA conformity assessment and subsequent inclusion on the Australian Register of Therapeutic Goods (ARTG).

The pathway to market to sell in Australia is significantly longer for local manufacturers compared to their overseas counterparts. Overseas manufacturers are able to prepare an Australian Declaration of Conformity using evidence from a third party notified body or the TGA. However, it is legislated that local manufacturers must solely rely on the TGA for Conformity Assessment Certification.

The crux of this issue is highlighted by the TGA’s reticence to provide timeline data for submissions and is further exemplified by the cognizance of EU notified bodies to client commercial deadlines.

In recent times, there has been industry groundswell for the introduction of third party conformity assessment for Australian manufacturers. Richard Walmsley CEO, raised this “elephant in the room” issue at the “The Modernisation of the TGA” AusMedtech session with Dr. Rohan Hammett, National Manager for the TGA. Interestingly, the TGA currently accepts overseas third party certifications for 97% of all conformity assessment reviews, however these services are currently denied to Australian manufacturers planning to supply in Australia.

Mr. Walmsley also advocates that mandatory timelines and application tracking be incorporated in TGA conformity assessment procedures so that local SMEs are not commercially disadvantaged by vacillating approval timelines. Although a hot issue in the industry, Dr. Hammett gave no indications that the TGA would be making any further announcements on the subject in the short term.

Image Below:

Richard Walmsley discussing third party conformity assessment with Dr. Rohan Hammett (TGA) at the recent AusMedtech 2011 Conference in Sydney

Picture Courtesy of Ray Messner Photography

1 - Ingeneus advocates change to the Therapeutic Goods Administration (TGA)